BeNeLuxBelgiumNetherlandsLuxembourg

EMA tests procedure for early stage drugs

26.10.2010

Brussels - Healthcare institutions from Europe have launched a new pilot
process testing multi-stakeholder consultations in early-stage drug
development. The purpose of the project is to reach an agreement about what
constitutes a medicine’s value and the evidence required to demonstrate that
value most effectively, the European Medicines Agency said on its website.
The initiative is funded by the companies AstraZeneca, GlaxoSmithKline and
Johnson & Johnson.
The pilot initiative involves clinicians, health technology assessors
(HTAs), patient representatives, payers, regulators and drug developers from
France, Germany, Italy, the Netherlands, Sweden, the United Kingdom and
staff from the European Medicines Agency.
Participating companies will seek early advice regarding a medicine under
development for the treatment of either breast cancer or type 2 diabetes,
with consultations planned over the next four months. The agreed
consultation process will engage all participants on issues of therapeutic
value and a narrower group of HTAs and payers on questions of economic value deriving from therapeutic benefits.
Consultation recommendations will be non-binding and will not supercede
existing advice processes. Participants anticipate that this experimental
initiative could help shape subsequent pilots and broader initiatives for
early consultation. The pilots arose from the European Healthcare Innovation
Leadership Network. The Network comprises healthcare leaders from across
Europe who are committed to addressing the complementary goals of improving patient health outcomes and enhancing the climate for in

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1983

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/ema-tests-procedure-for-early-stage-drugs.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • CYTOS0.28 CHF21.74%
  • CO.DON2.57 EUR7.08%
  • EPIGENOMICS5.12 EUR5.57%

FLOP

  • BIOTEST80.10 EUR-2.17%
  • WILEX2.15 EUR-1.83%
  • BIOFRONTERA2.46 EUR-1.60%

TOP

  • CYTOS0.28 CHF86.7%
  • EPIGENOMICS5.12 EUR49.7%
  • STRATEC BIOMEDICAL49.10 EUR30.9%

FLOP

  • BIOFRONTERA2.46 EUR-15.5%
  • ADDEX3.10 CHF-9.9%
  • CO.DON2.57 EUR-8.9%

TOP

  • SANTHERA90.75 CHF2569.1%
  • CO.DON2.57 EUR144.8%
  • BB BIOTECH180.60 EUR62.8%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.92 EUR-47.1%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 20.11.2014

Current issue

All issues